tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Mankind Pharma Receives ‘Adequate’ ESG Rating from Crisil

Story Highlights
Mankind Pharma Receives ‘Adequate’ ESG Rating from Crisil

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Mankind Pharma Ltd. ( (IN:MANKIND) ) has shared an update.

Mankind Pharma Ltd. has received an ESG rating of ‘Crisil ESG 57’ from Crisil ESG Ratings & Analytics Limited, indicating an ‘adequate’ level of environmental, social, and governance practices. This rating reflects the company’s efforts in maintaining transparency and responsibility in its operations, potentially impacting its reputation and attractiveness to investors focused on sustainable practices.

More about Mankind Pharma Ltd.

Mankind Pharma Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of a wide range of healthcare products. The company is known for its commitment to providing affordable and quality medicines, catering to both domestic and international markets.

Average Trading Volume: 19,120

Technical Sentiment Signal: Strong Buy

Current Market Cap: 1028.3B INR

See more data about MANKIND stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1